Nanjing Leads Biolabs Co.,Ltd
Nanjing Leads Biolabs Co.,Ltd
Explore linked clinical trials.13 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)] | Advanced Solid Tumour | Recruiting | Phase 2 | 2026-09-21 | NCT07111546 | |
| A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 1 / Phase 2 | 2026-09-11 | NCT06049290 | |
| A Clinical Trial of LBL-024 Combination Drug in Patients With Metastatic Colorectal Carcinoma | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Not yet recruiting | Phase 1 / Phase 2 | 2026-09-02 | NCT07791758 | |
| A Trial of LBL-024 Combined With Platinum-based Chemotherapy for the Treatment of Advanced EP-NEC | Advanced Extrapulmonary Neuroendocrine Carcinoma | Not yet recruiting | Phase 3 | 2026-09-01 | NCT07720193 | |
| A Study to Assess the Safety and PK/PD of LBL-047 in Healthy Adults and Patients With Systemic Lupus Erythematosus | Skin and Connective Tissue Diseases, autoimmune disease, connective tissue disorder, immune system disorder, systemic lupus erythematosus | Recruiting | Phase 1 | 2026-08-27 | NCT07323173 | |
| A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)] | Advanced Solid Tumour | Recruiting | Phase 2 | 2026-08-27 | NCT06783647 | |
| A Study of LBL-024 in Combination With Paclitaxel ± Bevacizumab for the Treatment of Platinum-resistant Ovarian Cancer | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder | Recruiting | Phase 1 / Phase 2 | 2026-08-13 | NCT07042802 | |
| A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors | Advanced Solid Tumor | Recruiting | Phase 1 / Phase 2 | 2026-06-30 | NCT05170958 | |
| A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)] | Advanced Solid Tumour | Recruiting | Phase 2 | 2026-05-18 | NCT07331155 | |
| A Trial of LBL-024 Monotherapy, LBL-024 Combined With LBL-007 or Toripalimab in Patients With Advanced Melanoma | Advanced Melanoma | Recruiting | Phase 1 / Phase 2 | 2026-05-18 | NCT07099430 | |
| A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04] | Advanced Solid Tumour | Recruiting | Phase 2 | 2026-05-13 | NCT07390383 | |
| A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma | Advanced Neuroendocrine Carcinoma | Recruiting | Phase 1 / Phase 2 | 2026-03-12 | NCT06157827 | |
| A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Recruiting | Phase 1 / Phase 2 | 2026-02-12 | NCT07281976 |